Mylan received an ANDA approval for gCopaxone 20mg/ml (branded market sales: USD600m) and 40mg/ml (branded market sales: USD2.2-2.3b). Mylan is the second generic filer to receive an approval for 20mg/ml (Sandoz/Momenta is already in the market). In 40mg/ml, Mylan is the first filer to receive an approval. Copaxone is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS). 40mg launch may happen at risk': Although the company will be launching 20mg/ml strength now, the 40mg/ml product is still under litigation. In January...